February 23, 2024

24/7 Market News Snapshot 08 Jan, 2024 – Cyclacel Pharmaceuticals Inc. (NYSE: CYCC)

Press Release

Last Price: $0.00 ▲ (+0.76%) +0.02  (2024-02-23 15:57) (Market Closed)

DENVER, Colo., 08 Jan, 2024 (www.247marketnews.com) – **FOR IMMEDIATE RELEASE**

BERKELEY HEIGHTS, N.J., January 09, 2024 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP; “Cyclacel”), an innovative biopharmaceutical company, has seamlessly achieved a significant milestone in its commitment to developing groundbreaking cancer treatments. The company proudly announces a robust 15.76% surge in stock price, an energizing vote of confidence from the market, indicated by the stock climbing to $2.8823, bolstered by an impressive volume of 3,067,968 shares traded.

This exhilarating market performance coincides with the company’s recent accomplishment in meeting the Nasdaq’s minimum bid price requirement for continued listing. With an official notice received on January 4, 2024, Cyclacel has confirmed its compliance with the Rule 5550(a)(2) after maintaining or exceeding the required bid price over the preceding 30 business days.

“We are truly gratified by our compliance with Nasdaq’s listing criteria, a testament to our team’s indefatigable effort and the solid trust from our investors in our strategic trajectory,” remarked the Cyclacel CEO. “This buoyant escalation in our stock is indeed a mirror reflecting not only the innovation inherent in our therapeutic endeavors but also our unwavering mission to pave new pathways in cancer care.”

Optimism runs high in the corridors of Cyclacel as the company continues to break ground in its clinical trial programs, aiming to pioneer new realms of therapeutic solutions for cancer patients. This latest financial triumph exemplifies Cyclacel’s dedication to both impeccable corporate governance and the profound impact its work has on patient welfare.

Cyclacel continues to prioritize transparency and maintain rigorous performance standards. The company is keen on nurturing its relationship with shareholders and looks forward to divulging further developments as they materialize.

For more details on Cyclacel’s journey, achievements, and updates on its compliance with Nasdaq Listing Rules, interested parties are invited to refer to the company’s website or reach out to the Investor Relations department.

Cyclacel Pharmaceuticals, Inc.
Investor Relations Department
[email address]
[phone number]


Legal Notice:
Statements in this press release with respect to Cyclacel Pharmaceuticals, Inc.’s (“the Company’s”) plans and its future financial performance are forward-looking statements that involve risk and uncertainty. The forward-looking statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances.

Source: Cyclacel Pharmaceuticals, Inc.
Connect with 24/7 Market News:


About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community.

24/7 Market News (24/7MN) is a third-party publisher and online news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, stock market blogs, and newsletters covering equities listed on the NYSE, NASDAQ, and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7 MN is not affiliated with any company written about in this release and owns no shares of stock. 24/7MN’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.
The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and based on publicly available information which is believed to be reliable.
The stocks and strategies discussed are simply ideas only and are in no way financial advice or recommendations. The author may or may not at any time be holding securities discussed. The author may or may not enter trades in the stocks mentioned. Some positions in mentioned stocks may already be held or are being adjusted or are simply examples, ideas or discussion topics. You are always trading at your own risk.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

24/7 Market News
[email protected]

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.